Article Text

Use of rituximab in paediatric nephrology
  1. Rajiv Sinha1,
  2. Nirav Agrawal2,
  3. Yuanxin Xue3,
  4. Rahul Chanchlani4,
  5. Subal Pradhan5,
  6. Rupesh Raina2,
  7. Stephen D Marks6,7
  1. 1 ICH, Institute of Child Health, Kolkata, India
  2. 2 Department of Nephrology, Akron Children's Hospital, Akron, Ohio, USA
  3. 3 Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
  4. 4 Division of Pediatric Nephrology, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
  5. 5 Department of Pediatrics, Sardar Vallabhbhai Patel Post Graduate Institute of Paediatrics(SVPPGIP), Cuttack, Odisha, India
  6. 6 Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
  7. 7 NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London Great Ormond Street Institute of Child Health, London, UK
  1. Correspondence to Dr Stephen D Marks, Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK; markss2{at}


Rituximab is a chimeric monoclonal antibody capable of depleting B cell populations by targeting the CD20 antigen expressed on the cell surface. Its use in oncology, initially in B cell lymphoma and post-transplant lymphoproliferative disorders, predates its current utility in various fields of medicine wherein it has become one of the safest and most effective antibody-based therapies. It was subsequently found to be effective for rheumatological conditions such as rheumatoid arthritis and antineutrophil cytoplasmic antibody-associated vasculitis. Over the past decade, rituximab has generated a lot of interest in nephrology and has become an emerging or accepted therapy for multiple renal conditions, including systemic lupus erythematosus, lupus nephritis, vasculitis, nephrotic syndrome and in different scenarios before and after kidney transplantation. This review outlines its current use in paediatric nephrology practice, focusing on the knowledge required for general paediatricians who may be caring for children prescribed this medication and reviewing them on a shared care basis.

  • nephrology
  • therapeutics

Data availability statement

No data are available.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from


Rituximab is a monoclonal antibody against the CD20 antigen on B lymphocytes, which was originally used successfully as intravenous treatment for B cell lymphoma in adults and children.1 Over the last two decades, it has been used more frequently in children with different kidney diseases, including systemic lupus erythematosus (SLE) and lupus nephritis, antineutrophil cytoplasmic antibody-associated vasculitis (AAV), nephrotic syndrome (NS) and kidney transplantation (KT). This review will investigate the scientific basis for the use of intravenous rituximab, with a focus on paediatric data accumulating over the last decade.

Molecular structure of rituximab

Rituximab is a chimeric IgG1 kappa type immunoglobulin antibody that induces B cell lysis. It is composed of a human constant sequence (Fc region) and mouse anti-CD20 variable sequence (Fab region) (figure 1A). It binds directly to the CD20 antigen, which is a non-glycosylated tetra-spanning phosphoprotein embedded in the cell membrane, restricted to cells of B cell lineage including pre-B cells, memory cells and B lymphocytes found in tissues such as the white pulp of the spleen and lymph nodes. Healthy plasma cells, pro-B cells or other normal tissues lack this specific antigen.2 After binding to rituximab, CD20 is translocated into lipid rafts, where it signals through tyrosine kinases, mitogen-activated protein kinases and phospholipase Cγ, to mediate the inhibition of B cell growth or induce apoptosis.3 4

Figure 1

(A) describes the molecular structure of rituximab, including the weight of the chains and the binding affinity. (B) explains how rituximab uses antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity (CDC), ultimately leading to cell lysis. This mechanism takes place with several effectors, macrophage, natural killer (NK) cells and neutrophils. In this figure, we focus on NK cells. Rituximab binds to the affected B cell (CD20) via the Fab portion and exposing the Fc region. The Fcy-RIII/CD16 receptor of NK cell binds to the Fc region of rituximab, forming a complex. Following its formation, the NK cell undergoes degranulation, releasing cytotoxins that mediate the lysis of the target cell. During the CDC, the rituximab antibody binds to the affected B cells (CD20) and causing activation of the complement cascade. This leads to the formation of the membrane attack complex, which induces cell lysis.

Pharmacodynamics and pharmacokinetics

Rituximab is administered intravenously, available as a clear, colourless, odourless and preservative-free liquid in 100 mg (10 mL) or 500 mg (50 mL) single-use vials at a concentration of 10 mg/mL. The product (brands include Rituxan and MabThera) is formulated in 9.0 mg/mL sodium chloride, 7.35 mg/mL sodium citrate dihydrate, 0.7 mg/mL polysorbate and sterile water, with the pH adjusted to 6.5 similar to other biosimilars available in the market.1 5 After administration, the rituximab antibody is disseminated throughout the body and binds to the CD20 antigen on normal or abnormal B cells. Rituximab is a large molecule, and pharmacokinetic studies have shown that it follows a two-compartment model with a terminal half life of 19–22 days.6 Although serum levels achieved have been found to be similar irrespective of age or dose (375 mg/m2 or 1000 mg/m2), multiple repeated doses have been shown to increase its serum level as well as prolong serum half-life.7–9 Continuation of maintenance immunosuppression following rituximab infusion has been shown to further prolong CD19 depletion.10 As rituximab elimination through urine is increased in significant proteinuria, it is usually advisable to achieve a complete remission prior to its administration. However, this may not always be possible as is the case with steroid-resistant nephrotic syndrome (SRNS), and repeated doses have been suggested to be useful in this cohort.11

Mechanism of action

Rituximab mediates its effect through various mechanisms, which allow it to be potentially useful across a wide range of kidney disorders:

  1. B cell depletion.

  2. Indirect/direct effect on T cells.

  3. Direct podocyte activity.

B cell depletion occurs through three main pathways

Antibody-dependent cell-mediated cytotoxicity (ADCC)

The rituximab antibody binds to the CD20 receptor through its Fab portion while exposing its Fc region for effector cells like natural killer cells, macrophages and neutrophils (figure 1B).12 13

Complement-dependent cytotoxicity (CDC)

Similar to ADCC, B cell lymphocytes form complexes with the rituximab antibody and activate the complement cascade, leading to formation of the membrane attack complex, which induces cell lysis.12 13

Direct effects on abnormal B cell lymphocytes

The mechanism behind the direct effect of rituximab on abnormal B cell lymphocytes is not completely understood. Once the complex is formed, the affected cell may directly undergo apoptosis, inhibition of proliferation and cell cycle alteration.1 13

B cell depletion is likely to reduce the production of abnormal autoreactive antibodies, which explains its postulated utility in various autoimmune nephrology disorders.

Effects on T cell lymphocytes

As B cells produce costimulatory signals following activation for T cells and cytokines that modulate T cell differentiation, B cell depletion can be beneficial in T cell mediated disorders. In addition, some T cells may have CD20 receptors that allow for direct effects of rituximab.14 Moreover, rituximab has been shown to modulate Treg and Breg cells, which were recently discovered to influence disease relapse/recurrence in NS.15–17

Direct action of rituximab on podocytes

Rituximab has been shown to bind to sphingomyelin-phosphodiesterase-acid-like-3b (SMPDL-3b) on the surfaces of podocytes that regulates acid-sphyngomyelinase activity and prevents disruption of the actin cytoskeleton and apoptosis of the podocyte.18 Although this mechanism is novel and interesting, its relevance in clinical use has been questioned after successful results in NS with other anti-CD20 antibodies that do not bind SMPDL-3b such as ofatumumab.19

Role of intravenous rituximab in paediatric nephrology

Nephrotic syndrome

The utility of rituximab for paediatric NS was serendipitously discovered when a child with frequently relapsing/steroid-dependent NS (FRNS/SDNS) was given rituximab for idiopathic thrombocytopaenic purpura. Alongside improved platelet counts, the sustained remission of NS was also noted.20 The excitement regarding this novel outcome was further reinforced by a case report, which demonstrated improvement in NS secondary to the recurrence of focal and segmental glomerulosclerosis (FSGS) post-transplantation, after receiving rituximab for post-transplant lymphoproliferative disorder (PTLD).21 Currently, although the mechanism of action for rituximab’s therapeutic effects remains uncertain, it has become an important tool in the arsenal of the paediatric nephrologist. Proteinuria in NS may be mediated by a yet unrecognised permeability factor(s) of T cell cytokine origin,22 and as discussed before, this can be modulated through B cell depletion by rituximab. As also mentioned before, rituximab has been show to have direct podocyte stabilisation effects, although its clinical relevance has been questioned.18 19 Modulation of Treg and B reg cell populations by rituximab has also been correlated with relapses in NS.15 Delayed reconstitution of switched memory B cells following rituximab administration is postulated to predict an effective response to rituximab.16 Similarly, the reduced production of cytokine IFN-gamma+CD3+ by T cells at baseline in FSGS patients has been significantly associated with a longer time to relapse.17

Up to 50% of children with NS develop FRNS/SDNS and require steroid-sparing agents including cyclophosphamide, mycophenolate mofetil (MMF) and calcineurin inhibitors (CNIs) such as tacrolimus or ciclosporin.23 All of these medications have potential for serious adverse effects (SAEs), including the CNI-induced nephrotoxicity, and apart from cyclophosphamide, they need to be given over a prolonged period. Rituximab has shown significant steroid-sparing and CNI-sparing potential among FRNS/SDNS (table 1). In a recent review on FRNS/SDNS, the use of rituximab was shown to result in an average remission of 12–20 weeks, reduced frequencies of relapse and reduction or discontinuation of corticosteroids and other immunosuppressive agents.24 Its significant steroid-sparing effect has been demonstrated to improve growth parameters that are crucial in paediatric practice.25 Studies have flagged up certain attributes with some practical utility. Older age at rituximab administration has been significantly associated with improved outcomes, such as a lower risk of relapse,10 26 longer time to B cell recovery27 and lower risk of hypogammaglobulinaemia17; however, these associations have not been universally confirmed.15 28 Despite its high cost, rituximab is postulated to be overall cost-effective as it may reduce the need for daily medications as well as the costs involved in regular drug level monitoring often needed for agents such as CNIs.29

Table 1

Relevant paediatric studies on use of rituximab in nephrotic syndrome (FRNS/SDNS and SRNS)

In contrast to the significant benefit seen with rituximab among SDNS/FRNS, the jury is still out on its utility among SRNS (table 1). Despite the positive reports of cohort and registry studies, the recent International Paediatric Nephrology Association guideline23 has given rituximab a weak recommendation (grade 2C) for use in SRNS in view of the negative results of the only randomised control trial (RCT) published to date.30 In terms of response, the effect of rituximab among SRNS can be modulated by various variables including the period of assessment postrituximab therapy, concomitant use of corticosteroids and other immunosuppressive agents, disease progression and underlying aetiologies, particularly those secondary to genetic origin. Systematic reviews of cohort studies have shown that over 50% of SRNS children resistant to CNI do respond to rituximab and achieve either complete or partial remission.31 Currently, no alternative agent in comparison with rituximab demonstrates superior add-on efficacy among CNI-resistant SRNS. The role of rituximab should be considered as even partial remission (compared to no response) in SRNS has demonstrated a significantly better renal prognosis.32


As immune dysregulation and antibody production is postulated to play an important role in both AAV (granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis) and SLE nephritis, the B cell depleting effect of rituximab is likely to be beneficial. AAV studies in adults, including RCTs, have demonstrated rituximab to be as effective as conventional therapy, obtaining remission in up to 80% of refractory patients.33 However, the same cannot be said for paediatric patients where the literature remains limited (table 2).34 Rituximab has been frequently used as an add-on for refractory cases in lupus nephritis and now is more routinely used even on initial presentation. A systematic review has shown that up to 33% of refractory lupus nephritis patients receiving rituximab show significant renal improvement including complete remission.35 However, add-on rituximab failed to show any benefit in the LUNAR trial, which was primarily an adult RCT for patients with lupus nephritis.36 However, retrospective data have consistently demonstrated it to be an effective add-on therapy with good steroid-sparing potential.37 Paediatric data in this field remain scarce and lack RCTs (table 2). Marks et al published the first series (n=7) of successfully treated children in 2005, which was subsequently updated to include 19 children in 2008.38 39 Despite complex SLE, an impressive clinical response was observed with a large majority of children experiencing reduced disease activity and about 50% going into full remission with significantly improved British Isles Lupus Assessment Group index, antibody and complement levels and haematological and renal parameters. Basu et al 40 conducted a comparative study in childhood-onset lupus nephritis patients. A total of 44 lupus nephritis pediatric patients were followed for 36 months, who received either rituximab, MMF or cyclophopshmide along with oral prednisolone (tapering dose). Patients who received rituximab showed significantly higher flare-free survival period than MMF and cyclophosphamide (p=0.006). There was also a decrease in the required daily dose of prednisone in the rituximab group (p=0.005). The authors concluded in favour of the relatively higher efficacy and medium safety of rituximab when compared with MMF or cyclophosphamide among children with lupus nephritis.

Table 2

Relevant paediatric studies on use of rituximab in AAV and SLE nephritis

Kidney transplantation

As B cells play an important role in antibody-mediated rejection (ABMR), rituximab is likely to be useful. A meta-analysis by Macklin et al 41 on primarily adult studies concluded that rituximab may be of some benefit in acute ABMR. However, they also stressed the lack of high-quality evidence that precludes any firm conclusions. In chronic ABMR, rituximab did not appear to reliably improve outcomes. Although paediatric data are limited, a small RCT42 has supported the use of rituximab for acute ABMR (table 3).

Table 3

Relevant paediatric studies on the use of rituximab in kidney transplantation

Approximately, a third of post-KT for end-stage kidney disease secondary to FSGS has recurrence of FSGS. Despite a lack of RCTs, there are encouraging paediatric case reports/series that have demonstrated some benefit of rituximab, although in most cases, it was used as an add-on with plasmapheresis and other immunosuppressant that precludes a firm conclusion (table 3).

Rituximab has become a standard part of the preconditioning protocol for ABO-incompatible (ABOi) transplantation (table 3). Maenosono et al 43 conducted a retrospective study among 115 adults receiving ABOi living donor kidney transplantation (LDKT). The study was divided into two groups: ‘good response’ or ‘poor response’ to rituximab therapy with response defined as per CD19+ cells counts. Patient belonging to good response group showed less antibody-mediated rejection than the poor response group (8% vs 22.5%, p=0.028, respectively). Similarly, a retrospective paediatric study comparing the ABOi LDKT (n=13) with ABO-compatible (ABOc) LDKT (n=37) with rituximab use among ABOi LDKT showed encouraging results with similar graft outcome. However, the use of rituximab had a higher number of late-onset neutropenia in the ABOi group than the ABOc group (p<0.001), requiring granulocyte colony-stimulating factor.44

Rituximab has been shown to be effective in PTLD.45 Among 27 patients developing PTLD postallogenic human stem cell transplantation, 20 patients showed complete response with rituximab with a 1-year overall survival of 46.8%.46

Dosing of rituximab

The initial dosing regimen of 4 weekly intravenous infusions of rituximab at 375 mg/m2 was borrowed from the treatment protocol for lymphoma and PTLD. Whether this high dose is required for children with kidney disorders is a pertinent question. Recently, Chan et al 10 published an international, multicentre retrospective review of 511 children with difficult SDNS/FRNS followed up for at least 18 months postrituximab therapy. In this large cohort, they examined the effect of rituximab at three dosing levels: low (375 mg/m2), medium (375 mg/m2 ×2) and high (375 mg/m2 ×3–4), with or without maintenance immunosuppression. Although the low dose rituximab had a significant higher relapse risk and shorter relapse-free period, differences were insignificant if maintenance immunosuppression (either MMF or CNI) was continued following rituximab therapy. This study supported the possibility of reducing dose frequency under the cover of continued immunosuppression. Although this may reduce both the costs of additional rituximab and the risks of its associated side effects, prospective controlled trials are needed before accepting it as the standard protocol.

B cell depletion and its reconstitution have been used as a marker of response to rituximab. Fujinaga et al 11 reported that early B cell recovery is associated with NS relapse, and most studies have shown that relapses usually occur after B cell reconstitution. However, there is no consensus regarding readministration of rituximab based on B cell recovery as not all children relapse once B cells repopulate.25 Measuring peripheral B cells (CD19 or CD20) may not demonstrate what is happening in the renal B cell population, and some units employ 6 monthly intravenous rituximab infusions irrespective of peripheral B cells counts in order to minimise or allow no immunosuppression in some patients groups (eg, adults with lupus nephritis). Registry data are required to capture the long-term effects of repeated doses of rituximab. NS relapses have also been associated with significant drops in Treg cells and alteration in IL-2 expression, accompanied with reconstitution of switched memory B cells.15 17 The relevance of these biomarkers in guiding subsequent dosing needs to be further explored.

Administration of rituximab

Prior to giving rituximab, some centres advocate investigations to rule out coexisting pulmonary tuberculosis (primarily in an endemic region) and test hepatitis B surface antigen. Children receiving rituximab are usually admitted to the hospital for a day, receiving premedication of chlorphenamine or hydroxyzine (0.5–1 mg/kg orally maximal at 100 mg), intravenous methylprednisolone (1 mg/kg maximal at 50 mg), paracetamol (10–15 mg/kg orally as required every 4 hours maximal at 1 g) and ondansetron (0.15 mg/kg/dose orally or intravenously maximal at 8 mg), administered 30 min before rituximab infusion. Rituximab is diluted to 1–4 mg/mL in 0.9% sodium chloride and administered initially at approximately 1 mL/kg/hour (maximum of 50 mL/hour), which is increased hourly by 1 mL/kg with close monitoring for any adverse reaction.

Immunisation postrituximab

Children receiving rituximab are usually immunocompromised due to B cell suppression and prone to various infections including those secondary to vaccine-preventable diseases. Unfortunately, the immunity among these children is often impaired even prior to rituximab administration, as they are likely to be on prolonged use of immunosuppressive agents. Their compromised immunity has quite commonly precluded an adequate response to vaccination and the use of live vaccines. Rituximab blunts both humoral and cellular response that influences vaccination schedules. Postrituximab B cell counts start to recover from 3 months onward but may take up to 12 months or longer to fully normalise. Although plasma cells initially produce antibodies, it is proposed that B cell depletion eventually decreases the overall production. Therefore, until B cell repopulation and restoration of normal antibody production occurs, vaccines are unlikely to be fully effective. Most centres are continuing to use rituximab during the COVID-19 pandemic, without increased risk of infection having been demonstrated in children, but there may be reduced response when vaccinations are introduced globally.

In the absence of publications on immunisation efficacy in renal disorders among children receiving rituximab, most of the conclusions are drawn from vaccination studies following rituximab use in rheumatological disorders.47 Although there is no universal accepted guideline, it is reasonable to agree on some basic points:

  1. With the exception of live vaccines, it is advisable to adhere to local guidelines irrespective of the underlying condition.

  2. Attempts should be made to ensure that all non-live vaccines are given at least 1 week before rituximab infusion.

  3. Live vaccines should be given at least 1 month prior to rituximab infusion, provided the child is not on any other immunosuppressants.

  4. Vaccination can be recommenced 6 months postrituximab, where the restoration of B cell populations and the ability to mount seroprotection are likely to have occurred.

  5. Live vaccines can also be given 6–9 months postrituximab provided the child is not on any other immunosuppressants.

  6. As the response to tetanus, vaccination may be decreased with rituximab, especially within the first 6 months of treatment, it is recommended that the tetanus immunoglobulin be administered if there is high risk of a contaminated wound.

Although rituximab impairs development of new immunity postvaccination, existing immunity may not be influenced significantly.47

Chemoprophylaxis of postrituximab therapy

Patients on rituximab are at higher risk of Pneumocystis jiroveci pneumonia, and some centres advocate the use of antibiotic prophylaxis (usually cotrimoxazole) until B cell recovery.23

Adverse effects of rituximab

Majority of studies on rituximab use in paediatric nephrology have reported an acceptable safety profile but caution is still warranted; a report from France showed mortality in 5 out of 98 subjects of NS within a year of rituximab.48

Infusion reactions appear to be the most common side effects (table 4) at an incidence of 9.1%–56.3%, typically occurring within 30–120 min of starting infusion.6 24 Fortunately, reactions are usually mild and improve with temporary discontinuation if needed. Infusions can often be restarted at a slower rate under antihistamine and corticosteroid cover, unless anaphylaxis is suspected.

Table 4

Immediate and long-term side effects of rituximab5 47–49 51

Infections remain the other concern (table 4). As rituximab spares plasma cells, serum immunoglobulin levels are typically normal, although persistent hypogammaglobulinaemia has been occasionally reported. In a long-term study on idiopathic NS, prolonged depletion of switch memory B cells and younger age at initial administration were significantly associated with low immunoglobulin levels following anti-CD20 treatment.17 Serious infections reported in both case reports/series and cohort studies are not very common. A meta-analysis of three RCTs of rituximab therapy in rheumatoid arthritis did not show any significant increase in the incidence of infections.49 In contrast, the use of rituximab in lymphomas has been associated with double the increased risk of neutropaenia and infection as well as potential reactivation of hepatitis B, resulting in fulminant hepatic failure.1 Late neutropaenia has been occasionally reported among NS along with associated complications such as infections with P. jiroveci.6 Although rare and not yet reported among primary renal disorders, a concern is the risk of progressive multifocal leucoencephalopathy, an encephalitis caused by JC polyomavirus and characterised by the gradual onset of cognitive impairment, motor weakness, speech problems and deterioration in vision.6 23 Another rare serious adverse event is the development of rituximab-associated lung injury.52 This usually occurs after multiple rituximab infusions (from 1 to 12 with mean of 4) and about 1–3 months after the last infusion. Pathologically, it is characterised by bronchiolitis obliterans organising pneumonia, interstitial pneumonitis, acute respiratory distress syndrome and hypersensitivity pneumonitis. Repeated doses of rituximab have been associated with the development of human antichimeric antibodies, which may cause anaphylactic reaction or decrease the efficiency of rituximab by increasing its clearance.

Other monoclonal antibodies

Humanised anti-CD20 and anti-CD22 monoclonal antibodies such as ofatumumab/ocrelizumab and epratuzumab, respectively, have been developed and studied. Belimumab, a human monoclonal antibody that inhibits the B cell activating factor, also known as B lymphocyte stimulator, has been developed as a specific drug for SLE. Recently, it has been shown to be effective in childhood lupus,50 and although children with severe active lupus nephritis were excluded, improvement was noted among those patients with lupus nephritis who were included in the study.


Rituximab has opened new avenues in the treatment of multiple paediatric nephrology disorders. Its effectiveness has been demonstrated in refractory NS, and it is likely to be useful among children with antibody-mediated nephrology disorders, particularly AAV and lupus nephritis and also in the field of KT. Slow infusion under a standard protocol with constant monitoring is important as infusion reactions are common. Despite its demonstrated utility, caution is justified as some studies have reported significant SAEs and the long-term outcomes remain unclear. Multiple questions need to be further explored, including the optimal frequency of redosing in NS, the monitoring requirement postrituximab (including monitoring of total leucocyte count, liver function test, CD19 and immunoglobulin levels) and the immunisation schedule following rituximab therapy.

Data availability statement

No data are available.

Ethics statements

Patient consent for publication


Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.


  • Contributors Both RS and NA should be credited as joint first author.

  • Funding This project was supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children National Health Service Foundation Trust and University College London.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.